154 related articles for article (PubMed ID: 36302963)
1. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration.
Yang K; Han W; Jiang X; Piffko A; Bugno J; Han C; Li S; Liang H; Xu Z; Zheng W; Wang L; Wang J; Huang X; Ting JPY; Fu YX; Lin W; Weichselbaum RR
Nat Nanotechnol; 2022 Dec; 17(12):1322-1331. PubMed ID: 36302963
[TBL] [Abstract][Full Text] [Related]
2. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity.
Dane EL; Belessiotis-Richards A; Backlund C; Wang J; Hidaka K; Milling LE; Bhagchandani S; Melo MB; Wu S; Li N; Donahue N; Ni K; Ma L; Okaniwa M; Stevens MM; Alexander-Katz A; Irvine DJ
Nat Mater; 2022 Jun; 21(6):710-720. PubMed ID: 35606429
[TBL] [Abstract][Full Text] [Related]
3. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation.
Luo Z; Liang X; He T; Qin X; Li X; Li Y; Li L; Loh XJ; Gong C; Liu X
J Am Chem Soc; 2022 Sep; 144(36):16366-16377. PubMed ID: 36037283
[TBL] [Abstract][Full Text] [Related]
4. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
5. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway.
Ding C; Song Z; Shen A; Chen T; Zhang A
Acta Pharm Sin B; 2020 Dec; 10(12):2272-2298. PubMed ID: 33354501
[TBL] [Abstract][Full Text] [Related]
6. Fine-tuning Bacterial Cyclic di-AMP Production for Durable Antitumor Effects Through the Activation of the STING Pathway.
Jiang Y; Li X; Qian F; Sun B; Wang X; Zhang Y; Zhang D; Geng M; Xie Z; Yang S
Research (Wash D C); 2023; 6():0102. PubMed ID: 37011280
[TBL] [Abstract][Full Text] [Related]
7. Targeting the stimulator of interferon genes (STING) in breast cancer.
Ying-Rui M; Bu-Fan B; Deng L; Rong S; Qian-Mei Z
Front Pharmacol; 2023; 14():1199152. PubMed ID: 37448962
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory microenvironment remodelling by tumour cells after radiotherapy.
McLaughlin M; Patin EC; Pedersen M; Wilkins A; Dillon MT; Melcher AA; Harrington KJ
Nat Rev Cancer; 2020 Apr; 20(4):203-217. PubMed ID: 32161398
[TBL] [Abstract][Full Text] [Related]
9. Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
Go EJ; Yang H; Park W; Lee SJ; Han JH; Kong SJ; Lee WS; Han DK; Chon HJ; Kim C
Small; 2023 Oct; 19(43):e2300544. PubMed ID: 37381624
[TBL] [Abstract][Full Text] [Related]
10. Global Proteomic Analyses of STING-Positive and -Negative Macrophages Reveal STING and Non-STING Differentially Regulated Cellular and Molecular Pathways.
Aryal UK; Hedrick V; Onyedibe KI; Sobreira TJP; Sooreshjani MA; Wang M; Gürsoy UK; Sintim HO
Proteomics Clin Appl; 2020 May; 14(3):e1900109. PubMed ID: 32065729
[TBL] [Abstract][Full Text] [Related]
11. Cyclic dinucleotides modulate induced type I IFN responses in innate immune cells by degradation of STING.
Rueckert C; Rand U; Roy U; Kasmapour B; Strowig T; Guzmán CA
FASEB J; 2017 Jul; 31(7):3107-3115. PubMed ID: 28396343
[TBL] [Abstract][Full Text] [Related]
12. Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel.
Wang F; Su H; Xu D; Dai W; Zhang W; Wang Z; Anderson CF; Zheng M; Oh R; Wan F; Cui H
Nat Biomed Eng; 2020 Nov; 4(11):1090-1101. PubMed ID: 32778697
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles.
Li X; Khorsandi S; Wang Y; Santelli J; Huntoon K; Nguyen N; Yang M; Lee D; Lu Y; Gao R; Kim BYS; de Gracia Lux C; Mattrey RF; Jiang W; Lux J
Nat Nanotechnol; 2022 Aug; 17(8):891-899. PubMed ID: 35637356
[TBL] [Abstract][Full Text] [Related]
14. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
[TBL] [Abstract][Full Text] [Related]
15. Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour.
Jeong SH; Yang MJ; Choi S; Kim J; Koh GY
Nat Commun; 2021 Jul; 12(1):4405. PubMed ID: 34285232
[TBL] [Abstract][Full Text] [Related]
16. The role of cGAS-STING signalling in liver diseases.
Chen R; Du J; Zhu H; Ling Q
JHEP Rep; 2021 Oct; 3(5):100324. PubMed ID: 34381984
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Kinase 1 (Chk1) inhibition fails to activate the Stimulator of Interferon Genes (STING) innate immune signalling in a human coculture cancer system.
Brooks T; Wayne J; Massey AJ
Mol Biomed; 2021 Jun; 2(1):19. PubMed ID: 35006469
[TBL] [Abstract][Full Text] [Related]
18. AMP-guided tumour-specific nanoparticle delivery via adenosine A1 receptor.
Dai T; Li N; Han F; Zhang H; Zhang Y; Liu Q
Biomaterials; 2016 Mar; 83():37-50. PubMed ID: 26773664
[TBL] [Abstract][Full Text] [Related]
19. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.
Da Y; Liu Y; Hu Y; Liu W; Ma J; Lu N; Zhang C; Zhang C
Oncoimmunology; 2022; 11(1):2054105. PubMed ID: 35371622
[TBL] [Abstract][Full Text] [Related]
20. Systemic Delivery of mPEG-Masked Trispecific T-Cell Nanoengagers in Synergy with STING Agonists Overcomes Immunotherapy Resistance in TNBC and Generates a Vaccination Effect.
Shen M; Chen C; Guo Q; Wang Q; Liao J; Wang L; Yu J; Xue M; Duan Y; Zhang J
Adv Sci (Weinh); 2022 Nov; 9(32):e2203523. PubMed ID: 36089659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
